| About the author: |
P. A. Orujova, N. H. Sultanova |
| Heading |
CLINICAL MEDICINE |
| Type of article |
Scentific article |
| Annotation |
Neonatal sepsis, a significant cause of infant mortality, necessitates early diagnosis for effective intervention. Current diagnostic markers, such as C-reactive protein and procalcitonin, exhibit limited sensitivity and specificity. This study investigates the potential of adenosine monophosphate-activated protein kinase and high-mobility group box1 protein levels as early diagnostic biomarkers for neonatal sepsis. We examined 143 neonates with suspected sepsis, analyzing clinical and laboratory data, including complete blood cell count, C-reactive protein, procalcitonin, fibrinogen, lactate, HCO3, and base excess levels, alongside adenosine monophosphate-activated protein kinase and high-mobility group box1 protein levels using enzyme-linked immunosorbent assay. Our findings indicate elevated adenosine monophosphate-activated protein kinase and high-mobility group box 1 levels in septic neonates compared to non-septic counterparts, with significant correlations between these markers and disease severity. These results suggest that adenosine monophosphate-activated protein kinase and high-mobility group box1 could serve as reliable biomarkers for early sepsis detection, potentially guiding timely and appropriate therapeutic interventions. Further research is recommended to validate these biomarkers' clinical utility in neonatal sepsis diagnosis. |
| Tags |
adenosine monophosphate-activated protein kinase,high-mobility group box1,neonate,sepsis |
| Bibliography |
- Klymenko TM, Kosenko KO. Dyferentsiynyy pidkhid do diahnostyky rannoho neonatalnoho sepsysuv peredchasno narodzhenykh ditey. Zdorovya Dytyny. Neonatolohiya. 2019;14(7):415–419. doi: 10.22141/2224-0551.14.7.2019.184621 [in Ukrainian]
- Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases. Expert Opin Ther Targets. 2018 Mar;22(3):263–277. doi: 10.1080/14728222.2018.14399242018
- Chang CC, Sia KC, Chang JF, Lin CM, Yang CM, Huang KY, Lin WN. Lipopolysaccharide promoted proliferation and adipogenesis of preadipocytes through JAK/STAT and AMPK-regulated cPLA2 expression. International Journal of Medical Science. 2019; 16(1): 167–179. doi: 10.7150/ijms.24068
- Chen R, Kang R, Tang D. The mechanism of HMGB1 secretion and release. Exp Mol Med. 2022 Feb;54(2):91–102. doi: 10.1038/s12276-022-00736-w.
- Choi IY, Ju C, Anthony Jalin AM, Lee DI, Prather PL, Kim WK. Activation of cannabinoid CB2 receptor-mediated AMPK/CREB pathway reduces cerebral ischemic injury. Am J Pathol. 2013 Mar;182(3):928–39. doi: 10.1016/j.ajpath.2012.11.024.
- Deng M, Scott MJ, Fan J, Billiar TR. Location is the key to function: HMGB1 in sepsis and trauma-induced inflammation. J Leukoc Biol. 2019 Jul;106(1):161–169. doi: 10.1002/JLB.3MIR1218-497R.
- Hardie DG. AMPK: a target for drugs and natural products with effects on both diabetes and cancer. Diabetes. 2013 Jul;62(7):2164–72. doi: 10.2337/db13-0368.
- Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012 Jan 31;8(4):195–202. doi: 10.1038/nrrheum.2011.222.
- Irahara T, Sato N, Otake K, Matsumura S, Inoue K, Ishihara K, et al. Alterations in energy substrate metabolism in mice with different degrees of sepsis. J Surg Res. 2018 Jul; 227:44–51. doi: 10.1016/j.jss.2018.01.021.
- Lee SA, Kwak MS, Kim S, Shin JS. The role of high mobility group box 1 in innate immunity. Yonsei Med J. 2014 Sep;55(5):1165–76. doi: 10.3349/ymj.2014.55.5.1165.
- Li L, Lu YQ. The Regulatory Role of High-Mobility Group Protein 1 in Sepsis-Related Immunity. Front Immunol. 2021 Jan 22; 11:601815. doi: 10.3389/fimmu.2020.601815
- Liu L, Oza S, Hogan D, Chu Y, Perin J, Zhu J, et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. Lancet. 2016 Dec 17;388(10063):3027–3035. doi: 10.1016/S0140-6736(16)31593-8.
- Poggi C, Dani C. Sepsis and Oxidative Stress in the Newborn: From Pathogenesis to Novel Therapeutic Targets. Oxid Med Cell Longev. 2018 Aug 2; 2018:9390140. doi: 10.1155/2018/9390140.
- Stevens NE, Chapman MJ, Fraser CK, Kuchel TR, Hayball JD, Diener KR. Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes. Sci Rep. 2017 Jul 19;7(1):5850. doi: 10.1038/s41598-017-06205-z.
- Tarasiuk O, Miceli M, Di Domizio A, Nicolini G. AMPK and Diseases: State of the Art Regulation by AMPK-Targeting Molecules. Biology (Basel). 2022 Jul 11;11(7):1041. doi: 10.3390/biology11071041.
|
| Publication of the article |
«World of Medicine and Biology» №2(88), 2024 year, 104-108 pages, index UDK 616.94-053.3-036.1:577 |
| DOI |
10.26724/2079-8334-2024-2-88-104-108 |
